World ‘unprepared’ for next pandemic as countries fail to agree on sharing information, tests and vaccines

Negotiators missed the deadline to finalize the WHO pandemic treaty’s pathogen access and benefit-sharing system, leaving the agreement incomplete ahead of the World Health Assembly. The treaty was previously passed in May 2025, but it cannot open for signature until the annex is finished, with a new target now suggested for the 2027 World Health Assembly. The delay highlights ongoing mistrust between richer and poorer countries and keeps uncertainty elevated around future global pandemic preparedness and pharma access rules.

Analysis

The immediate market read-through is less about a direct earnings hit and more about an extended policy overhang for the global vaccine/diagnostics supply chain. The longer the treaty framework stays unresolved, the more procurement remains fragmented by jurisdiction, which favors incumbents with existing bilateral manufacturing footprints and pricing power over smaller platform biotech names that would have benefited from a more standardized access regime.

Second-order, the delay preserves optionality for governments to keep pushing for compulsory-access provisions, which is a medium-term margin risk for large-cap vaccine and antiviral developers if the eventual annexe hardens toward mandatory sharing. That said, the incremental impact is asymmetric: the downside is mostly on future peak-margin assumptions, while near-term revenues are likely unchanged. The bigger winner over the next 12-24 months is still contract manufacturing, fill-finish, cold-chain logistics, and diagnostics distribution, because prolonged uncertainty pushes governments to pre-position capacity rather than rely on treaty-led coordination.

The contrarian view is that this delay may actually be bullish for select biotech because it reduces the probability of a near-term IP compromise being forced through in a low-trust political environment. If negotiations slip to 2027, the market should treat the treaty as a slow-moving tail risk rather than a catalyst, and price action in vaccine names may be over-discounting a process that can still be diluted by implementation details. The real catalyst is not the announcement of a treaty, but whether the annexe ultimately introduces enforceable revenue-sharing or remains largely voluntary.

From a trading perspective, the most actionable expression is a relative-value long in businesses that monetize public-health preparedness without being hostage to treaty economics, versus short or underweight high-expectation pandemic vaccine platforms with elevated policy beta. Any material outbreak would flip this immediately, but absent that, the next 6-18 months should be driven by legislative drip risk rather than fundamental demand shock.

Key Decisions for Investors

• Long TMO / short BNTX as a 6-12 month pair: TMO benefits from persistent diagnostics, lab services, and manufacturing outsourcing demand; BNTX carries more treaty/IP-policy overhang if mandatory sharing language resurfaces. Target 8-12% relative return; cut if annexe progress turns explicitly voluntary.
• Overweight MRNA on a 12-month basis only on drawdowns, not headline risk: the treaty delay reduces near-term compulsory-access pressure, but the position should be sized small because a 2027 ratification path keeps policy convexity alive. Use a 10-15% trailing stop.
• Long DHR or A on weakness as a quality hedge against pandemic-policy uncertainty: both are better insulated through diversified tools and consumables exposure, with less dependence on treaty outcomes. Favor 6-9 month horizon for 5-8% upside with lower regulatory beta.
• Avoid initiating fresh longs in pure-play pandemic vaccine beneficiaries until the annexe is finalized: the risk/reward is poor because any mandatory Pabs language would compress future margin assumptions faster than consensus expects.
• If a specific outbreak headline emerges, shift immediately to a tactical long basket of TMO/BDX/ILMN versus short highly levered vaccine beta names; otherwise, keep the trade as a slow-burn policy pair rather than a catalyst trade.